Citadel Advisors’s Bionano Genomics BNGO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-419
Closed -$7.25K 14511
2024
Q4
$7.25K Sell
419
-307
-42% -$5.25K ﹤0.01% 13745
2024
Q3
$19.8K Sell
726
-395
-35% -$12.3K ﹤0.01% 12784
2024
Q2
$45.6K Buy
1,121
+574
+105% +$31.5K ﹤0.01% 11868
2024
Q1
$36.4K Buy
547
+306
+127% +$22.8K ﹤0.01% 12492
2023
Q4
$27.4K Sell
241
-233
-49% -$24.3K ﹤0.01% 12340
2023
Q3
$86.1K Buy
474
+220
+87% +$57.6K ﹤0.01% 11076
2023
Q2
$92.8K Sell
254
-259
-50% -$117K ﹤0.01% 11047
2023
Q1
$342K Sell
513
-425
-45% -$377K ﹤0.01% 9111
2022
Q4
$822K Sell
938
-152
-14% -$191K ﹤0.01% 7186
2022
Q3
$1.2M Buy
1,090
+487
+81% +$643K ﹤0.01% 6600
2022
Q2
$499K Buy
603
+226
+60% +$233K ﹤0.01% 8653
2022
Q1
$584K Sell
377
-387
-51% -$522K ﹤0.01% 9020
2021
Q4
$1.37M Sell
764
-335
-30% -$896K ﹤0.01% 7106
2021
Q3
$3.63M Sell
1,099
-431
-28% -$1.51M ﹤0.01% 4951
2021
Q2
$6.73M Sell
1,530
-270
-15% -$1.07M ﹤0.01% 3823
2021
Q1
$8.73M Buy
+1,800
New +$10.1M ﹤0.01% 3189

Other funds holding BNGO

Citadel Advisors's BNGO Position: Q1 2025 in Review

Citadel Advisors held its Bionano Genomics (BNGO) position steady in Q1 2025 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #14510.

Citadel Advisors first reported a position in BNGO in Q2 2020 and has held it in 15 quarters since. The position peaked at $20.4M in Q1 2021. 30 funds tracked by Wall St. Rank hold BNGO as of Q1 2025.

  • Citadel Advisors held 0 shares of Bionano Genomics worth $0 as of Q1 2025.
  • Citadel Advisors left its Bionano Genomics share count unchanged in Q1 2025.
  • Bionano Genomics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2025, its #14510 holding.
  • Citadel Advisors first reported a position in Bionano Genomics in Q2 2020 and has held it in 15 quarters since.
  • Citadel Advisors's Bionano Genomics position peaked at $20.4M in Q1 2021.
  • 30 funds tracked by Wall St. Rank held Bionano Genomics as of Q1 2025.

Based on Citadel Advisors's 13F filing for Q1 2025, filed 15 May 2025.